XOMA Corporation (XOMA) Shares are Down -3.72%

XOMA Corporation (XOMA) has risen sharply, recording gains of 6.67% in the past 4 weeks. However, the stock has corrected -3.72% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 6.26% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

XOMA Corporation has dropped 13.24% during the last 3-month period . Year-to-Date the stock performance stands at -55.64%. The stock has recorded a 20-day Moving Average of 2.85% and the 50-Day Moving Average is 2.09%.


XOMA Corporation (NASDAQ:XOMA): The stock opened at $0.61 on Friday but the bulls could not build on the opening and the stock topped out at $0.62 for the day. The stock traded down to $0.59 during the day, due to lack of any buying support eventually closed down at $0.59 with a loss of -2.59% for the day. The stock had closed at $0.61 on the previous day. The total traded volume was 454,170 shares.

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.